Unambiguous disclosure without patent profanity (T 2171/21)
The IPKat
DECEMBER 20, 2023
Striking the middle ground between satisfying the strict basis requirement in Europe and avoiding patent profanity in the US, renders the decision of when to file a patent application all the more critical. The Novartis patent EP 3111954 in T 2171/21 related to the second medical use of the anti-IL-17 antibody secukinumab.
Let's personalize your content